Go to
current issue
-
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70 Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Matthias May, Ingmar Wolff, Sabine D. Brookman-May
Abstract not available
-
Reply to André Pontes-Silva’s Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70 Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Gabriela Ilie, Robert David Harold Rutledge
Abstract not available
-
Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May’s Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol 2023;83:561–70 Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Gabriela Ilie, Robert David Harold Rutledge
Abstract not available
-
Re: Low Cancer Yield in PI-RADS 3 Upgraded to 4 by Dynamic Contrast-enhanced MRI: Is It Time To Reconsider Scoring Categorization? Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Sriram Deivasigamani, Srinath Kotamarti, Rajan T. Gupta, Thomas J. Polascik
Abstract not available
-
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Daniela-Elena Oprea-Lager, Steven MacLennan, Anders Bjartell, Alberto Briganti, Irene A. Burger, Igle de Jong, Maria De Santis, Uta Eberlein, Louise Emmett, Karim Fizazi, Silke Gillessen, Ken Herrmann, Sandra Heskamp, Andrei Iagaru, Barbara Alicja Jereczek-Fossa, Jolanta Kunikowska, Marnix Lam, Cristina Nanni, Joe M. O'Sullivan, Valeria Panebianco, Stefano Fanti
Background In prostate cancer (PCa), questions remain on indications for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging and PSMA radioligand therapy, integration of advanced imaging in nomogram-based decision-making, dosimetry, and development of new theranostic applications. Objective We aimed to critically review developments in molecular hybrid imaging and systemic
-
Re: MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy Eur. Urol. (IF 23.4) Pub Date : 2023-09-22 Laurence Klotz
Abstract not available
-
Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer Eur. Urol. (IF 23.4) Pub Date : 2023-09-16 Trine Strandgaard, Iver Nordentoft, Karin Birkenkamp-Demtröder, Liina Salminen, Frederik Prip, Julie Rasmussen, Tine Ginnerup Andreasen, Sia Viborg Lindskrog, Emil Christensen, Philippe Lamy, Michael Knudsen, Torben Steiniche, Jørgen Bjerggaard Jensen, Lars Dyrskjøt
Background Field cancerization is characterized by areas of normal tissue affected by mutated clones. Bladder field cancerization may explain the development and recurrence of bladder cancer and may be associated with treatment outcomes. Objective To investigate the predictive and prognostic roles of field cancerization in patients with high-risk non–muscle-invasive bladder cancer (NMIBC) treated with
-
Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U Eur. Urol. (IF 23.4) Pub Date : 2023-09-12 Hendrik Van Poppel, Monique J. Roobol, Arunah Chandran
Abstract not available
-
-
-
-
-
Re: David-Dan Nguyen, Liam Murad, Anne Xuan-Lan Nguyen, et al. Industry Payments to American Editorial Board Members of Major Urology Journals. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.04.017 Eur. Urol. (IF 23.4) Pub Date : 2023-09-14 Anju Murayama
Abstract not available
-
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance Eur. Urol. (IF 23.4) Pub Date : 2023-09-14 Srikala S. Sridhar, Thomas Powles, Miguel Á. Climent Durán, Se Hoon Park, Francesco Massari, Antoine Thiery-Vuillemin, Begoña P. Valderrama, Anders Ullén, Norihiko Tsuchiya, Jeanny B. Aragon-Ching, Shilpa Gupta, Daniel P. Petrylak, Joaquim Bellmunt, Jing Wang, Robert J. Laliberte, Alessandra di Pietro, Nuno Costa, Petros Grivas, Cora N. Sternberg, Yohann Loriot
Background In the JAVELIN Bladder 100 phase 3 trial, avelumab first-line maintenance + best supportive care (BSC) prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (advanced UC) without progression after first-line platinum-based chemotherapy. Objective To report post hoc analyses of subgroups defined by the duration
-
Reply to Laura E. Davis, Adam Calaway, and Laura Bukavina’s Letter to the Editor re: Nima Nassiri, Giovanni Cacciamani, Inderbir S. Gill. Robotic Bladder Auto-transplantation in a Heart-beating Brain-dead Human Research Donor. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.06.004 Eur. Urol. (IF 23.4) Pub Date : 2023-09-14 Nima Nassiri, Giovanni E. Cacciamani, Inderbir S. Gill
Abstract not available
-
Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023 Eur. Urol. (IF 23.4) Pub Date : 2023-09-10 Kentaro Inamura
Abstract not available
-
Re: Genetically Adjusted PSA Levels for Prostate Cancer Screening Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Martin C. Michel
Abstract not available
-
Re: Deep Learning Imaging Features Derived from Kidney Ultrasounds Predict Chronic Kidney Disease Progression in Children with Posterior Urethral Valves Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Lisette A. 't Hoen
Abstract not available
-
Re: Holmium Laser Enucleation of the Prostate Is Associated with Complications and Sequelae Even in the Hands of an Experienced Surgeon Following Completion of the Learning Curve Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Christopher Netsch
Abstract not available
-
Re: Stavros Gravas, Mauro Gacci, Christian Gratzke, et al. Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol. 2023;84:207–22 Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Francesco Montorsi, Paolo Capogrosso, Federico Dehò, Andrea Salonia
Abstract not available
-
Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Joana B. Neves, Hannah Warren, Joseph Santiapillai, Nicola Rode, David Cullen, Menelaos Pavlou, Miles Walkden, Prasad Patki, Ravi Barod, Faiz Mumtaz, Michael Aitchison, Steven Bandula, Elena Pizzo, Veronica Ranieri, Norman Williams, William Wildgoose, Kurinchi Gurusamy, Mark Emberton, Axel Bex, Maxine G.B. Tran
There is a paucity of high-level evidence on small renal mass (SRM) management, as previous classical randomised controlled trials (RCTs) failed to meet accrual targets. Our objective was to assess the feasibility of recruitment to a cohort-embedded RCT comparing cryoablation (CRA) to robotic partial nephrectomy (RPN). A total of 200 participants were recruited to the cohort, of whom 50 were enrolled
-
Re: Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Mikkel Fode, Christian Fuglesang S. Jensen, Jens Sønksen
Abstract not available
-
Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023; 388:1547–58 Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Bernardo Rocco, Maria Chiara Sighinolfi
Abstract not available
-
Re: Nima Nassiri, Giovanni Cacciamani, Inderbir S. Gill. Robotic Bladder Auto-transplantation in a Heart-beating Brain-dead Human Research Donor. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.06.004 Eur. Urol. (IF 23.4) Pub Date : 2023-09-09 Laura E. Davis, Adam Calaway, Laura Bukavina
Abstract not available
-
The Role of 99mTc‐Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta‐analysis Eur. Urol. (IF 23.4) Pub Date : 2023-09-05 Giuseppe Basile, Giuseppe Fallara, Paolo Verri, Alessandro Uleri, Arturo Chiti, Luigi Gianolli, Gino Pepe, Alessandro Tedde, Ferran Algaba, Angelo Territo, Francesco Sanguedolce, Alessandro Larcher, Andrea Gallioli, Joan Palou, Francesco Montorsi, Umberto Capitanio, Alberto Breda
Context The diagnostic accuracy of current imaging techniques in differentiating benign from malignant neoplasms in the case of indeterminate renal masses is still suboptimal. Objective To evaluate the diagnostic accuracy of 99mTc-sestamibi (SestaMIBI) single-photon emission tomography computed tomography (SPECT)/CT in characterizing indeterminate renal masses by differentiating renal oncocytoma and
-
Metaverse Surgical Planning with Three-dimensional Virtual Models for Minimally Invasive Partial Nephrectomy Eur. Urol. (IF 23.4) Pub Date : 2023-09-04 Enrico Checcucci, Daniele Amparore, Gabriele Volpi, Sabrina De Cillis, Federico Piramide, Paolo Verri, Alberto Piana, Michele Sica, Cecilia Gatti, Paolo Alessio, Alberto Quarà, Mariano Burgio, Marco Colombo, Giovanni Busacca, Alex Mottrie, Edward Cherullo, Alberto Breda, Alessandro Antonelli, Renaud Bollens, Andrea Minervini, Francesco Porpiglia
The recent integration of new virtual visualization modalities with artificial intelligence and high-speed internet connection has opened the door to the advent of the metaverse in medicine. In this totally virtual environment, three-dimensional virtual models (3DVMs) of the patient’s anatomy can be visualized and discussed via digital avatars. Here we present for the first time a metaverse preoperative
-
Reply to Thomas Seisen, Morgan Rouprêt, and Pierre Blanchard’s Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669–81 Eur. Urol. (IF 23.4) Pub Date : 2023-09-01 Alexandre R. Zlotta, Katherine Lajkosz, Jason A. Efstathiou
Abstract not available
-
Re: Petros Grivas, Se Hoon Park, Eric Voog, et al. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial. Eur Urol 2023;84:95–108 Eur. Urol. (IF 23.4) Pub Date : 2023-08-31 Yao-Ning Feng, Guang-Yu Xie, Li Xiao
Abstract not available
-
Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur. Urol. (2023)] Eur. Urol. (IF 23.4) Pub Date : 2023-09-02 Elizabeth R. Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delphine Borchiellini, Raymond S. McDermott, Ihor Vynnychenko, Yen-Hwa Chang, Satoshi Tamada, Michael B. Atkins, Chenxiang Li, Rodolfo Perini, L. Rhoda Molife, Jens Bedke, Brian I. Rini
Abstract not available
-
Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol 2023;84:109–16 Eur. Urol. (IF 23.4) Pub Date : 2023-09-01 Jonas Saal, Viktor Grünwald, Niklas Klümper
Abstract not available
-
Reply to Bernardo Rocco and Maria Chiara Sighinolfi’s Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547–58 Eur. Urol. (IF 23.4) Pub Date : 2023-09-01 Freddie C. Hamdy, Jenny L. Donovan
Abstract not available
-
Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669–81 Eur. Urol. (IF 23.4) Pub Date : 2023-08-31 Thomas Seisen, Morgan Rouprêt, Pierre Blanchard
Abstract not available
-
Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression Eur. Urol. (IF 23.4) Pub Date : 2023-08-31 Alexandros Papachristodoulou, Isabel Heidegger, Renu K. Virk, Matteo Di Bernardo, Jaime Y. Kim, Caroline Laplaca, Florencia Picech, Georg Schäfer, Guarionex Joel De Castro, Hanina Hibshoosh, Massimo Loda, Helmut Klocker, Mark A. Rubin, Tian Zheng, Mitchell C. Benson, James M. McKiernan, Aditya Dutta, Cory Abate-Shen
Background The antidiabetic drug metformin has known anticancer effects related to its antioxidant activity; however, its clinical benefit for prostate cancer (PCa) has thus far been inconclusive. Here, we investigate whether the efficacy of metformin in PCa is related to the expression status of NKX3.1, a prostate-specific homeobox gene that functions in mitochondria to protect the prostate from aberrant
-
Aggravated Androgen Receptor Activity in Otherwise Indolent Prostate Cancer Eur. Urol. (IF 23.4) Pub Date : 2023-08-25 Shawn E. Lupold, William B. Isaacs, Jun Luo
Abstract not available
-
Social Media Interventions for Patients and Public: Opportunities and Challenges for the Urology Community Eur. Urol. (IF 23.4) Pub Date : 2023-08-25 Nikita R. Bhatt, Jeremy Yuen-Chun Teoh, Esther Garcia Rojo, Vineet Gauhar, Claudia Mercader, Vito Cucchiara, Carla Bezuidenhout, Eamonn Rogers, Maria J. Ribal, Gianluca Giannarini
Abstract not available
-
Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burtt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. Eur Urol 2023;83:534–47 Eur. Urol. (IF 23.4) Pub Date : 2023-08-19 Paolo Capogrosso, Federico Dehò, Andrea Salonia, Alberto Briganti, Francesco Montorsi
Abstract not available
-
Re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol 2023;83:571–9 Eur. Urol. (IF 23.4) Pub Date : 2023-08-16 Xiao Li, Zicheng Xu, Feng Qi
Abstract not available
-
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605 Eur. Urol. (IF 23.4) Pub Date : 2023-08-16 Peter C. Black, Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance, Vadim S. Koshkin, Kelly L. Stratton, Trinity J. Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Ian M. Thompson, Seth P. Lerner
Background Although radical cystectomy (RC) is the standard of care for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), many patients are ineligible for surgery or elect bladder preservation. Objective To evaluate the efficacy and safety of atezolizumab in BCG-unresponsive high-risk NMIBC. Design, setting, and participants This was a single-arm
-
Reply to Xiao Li, Zicheng Xu, and Feng Qi’s Letter to the Editor re: Soumyajit Roy, Yilun Sun, Scott C. Morgan, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol 2023;83:571–9 Eur. Urol. (IF 23.4) Pub Date : 2023-08-16 Soumyajit Roy, Yilun Sun, Scott Morgan, Shawn Malone
Abstract not available
-
Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non–muscle-invasive Bladder Cancer. NEJM Evid 2022;1:EVIDoa2200092 Eur. Urol. (IF 23.4) Pub Date : 2023-08-12 Jonathan Sussman, Badrinath Konety, Hamed Ahmadi
Abstract not available
-
-
-
-
-
How Well Do Artificial Intelligence Chatbots Respond to the Top Search Queries About Urological Malignancies? Eur. Urol. (IF 23.4) Pub Date : 2023-08-10 David Musheyev, Alexander Pan, Stacy Loeb, Abdo E. Kabarriti
Artificial intelligence (AI) chatbots are becoming a popular source of information but there are limited data on the quality of information on urological malignancies that they provide. Our objective was to characterize the quality of information and detect misinformation about prostate, bladder, kidney, and testicular cancers from four AI chatbots: ChatGPT, Perplexity, Chat Sonic, and Microsoft Bing
-
Corrigendum to “Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials” [Eur Urol. 2023;84:393–405] Eur. Urol. (IF 23.4) Pub Date : 2023-08-09 Pramit Khetrapal, Joanna Kae Ling Wong, Wei Phin Tan, Thiara Rupasinghe, Wei Shen Tan, Stephen B. Williams, Stephen A. Boorjian, Carl Wijburg, Dipen J. Parekh, Peter Wiklund, Nikhil Vasdev, Muhammad Shamim Khan, Khurshid A. Guru, James W.F. Catto, John D. Kelly
Abstract not available
-
Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review Eur. Urol. (IF 23.4) Pub Date : 2023-08-05 Robert J. Motzer, Pratik P. Rane, Todd L. Saretsky, Deepshikha Pawar, Allison Martin Nguyen, Murali Sundaram, Joseph Burgents, Rishabh Pandey, Katja Rudell
Context In the oncology setting, patient-reported outcome measures (PROMs) provide important data that help to ensure patient-relevant endpoints are captured and reported. Use of this information for treatment decision-making by clinicians and patients in real-world settings is facilitated by consistent and transparent reporting of trial methods. Objective To identify and compare PROMs used in advanced
-
Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now Eur. Urol. (IF 23.4) Pub Date : 2023-07-28 Frédéric Pouliot, Louise Emmett
Abstract not available
-
Does Urologist-level Utilization of Active Surveillance for Low-risk Prostate Cancer Correspond with Utilization of Active Surveillance for Small Renal Masses? Eur. Urol. (IF 23.4) Pub Date : 2023-07-26 Michael Wang, Sophie Wittenberg, Michael L. Cher, Monica Van Til, Stephanie Ferrante, Mahin Mirza, Anna Johnson, Alice Semerjian, Arvin George, Craig Rogers, Samantha Wilder, Richard Sarle, Khurshid R. Ghani, Brian Lane, Kevin B. Ginsburg
Active surveillance (AS) for prostate cancer (CaP) or small renal masses (SRMs) helps in limiting the overtreatment of indolent malignancies. Implementation of AS for these conditions varies substantially across individual urologists. We examined the Michigan Urological Surgery Improvement Collaborative (MUSIC) registry to assess for correlation of AS between patients with low-risk CaP and patients
-
The Impact of Lineage-specific Transcriptional Factors in Small-cell Bladder Cancer in the Patient Selection Process in Future Clinical Trials Eur. Urol. (IF 23.4) Pub Date : 2023-07-26 Giuseppe Basile, Francois Audenet, Thomas Seisen, Benjamin Pradere
Abstract not available
-
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma Eur. Urol. (IF 23.4) Pub Date : 2023-07-26 Thomas Powles, Zoe June Assaf, Viraj Degaonkar, Petros Grivas, Maha Hussain, Stephane Oudard, Jürgen E. Gschwend, Peter Albers, Daniel Castellano, Hiroyuki Nishiyama, Siamak Daneshmand, Shruti Sharma, Himanshu Sethi, Alexey Aleshin, Yi Shi, Nicole Davarpanah, Corey Carter, Joaquim Bellmunt, Sanjeev Mariathasan
Background Interim results from IMvigor010 showed an overall survival (OS) benefit for adjuvant atezolizumab (anti–PD-L1) versus observation in patients with circulating tumor DNA (ctDNA)-positive muscle-invasive urothelial carcinoma (MIUC). Objective To report updated OS and safety by ctDNA status. Design, setting, and participants This ad hoc analysis from a global, open-label, randomized, phase
-
Reply to Deng-Xiong Li, De-Chao Feng, and Shi Deng’s Letter to the Editor re: Gyrithe Lynghøj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthøj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Eur. Urol. (IF 23.4) Pub Date : 2023-07-26 Gyrithe Lynghøj Pedersen, Karin Mogensen, Susanne Rosthøj, Gregers Gautier Hermann
Abstract not available
-
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study Eur. Urol. (IF 23.4) Pub Date : 2023-07-25 Elizabeth R. Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frédéric Pouliot, Bohuslav Melichar, Denis Soulières, Delphine Borchiellini, Raymond S. McDermott, Ihor Vynnychenko, Yen-Hwa Chang, Satoshi Tamada, Michael B. Atkins, Chenxiang Li, Rodolfo Perini, L. Rhoda Molife, Jens Bedke, Brian I. Rini
Previous analyses of KEYNOTE-426, an open-label, phase 3 randomized study, showed superior efficacy of first-line pembrolizumab plus axitinib to sunitinib in advanced clear cell renal cell carcinoma (ccRCC). We report results of the final protocol-prespecified analysis of KEYNOTE-426. Patients received pembrolizumab 200 mg intravenously every 3 wk plus axitinib 5 mg orally twice daily or sunitinib
-
Re: Elizabeth J. Schafer, Ahmedin Jemal, Daniel Wiese, et al. Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. Eur Urol. 2023;84:117–26 Eur. Urol. (IF 23.4) Pub Date : 2023-07-22 Po-Ren Hsiao, Wen-Wei Sung
Abstract not available
-
Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial Eur. Urol. (IF 23.4) Pub Date : 2023-07-21 Loïc Djaïleb, Wesley R. Armstrong, Daniel Thompson, Andrei Gafita, Andrea Farolfi, Abhejit Rajagopal, Tristan R. Grogan, Kathleen Nguyen, Matthias R. Benz, Masatoshi Hotta, Francesco Barbato, Francesco Ceci, Sarah M. Schwarzenböck, Marcus Unterrainer, Helle D. Zacho, Roxanna Juarez, Matthew Cooperberg, Peter Carroll, Samuel Washington, Robert E. Reiter, Jeremie Calais
Background In the initial staging of patients with high-risk prostate cancer (PCa), prostate-specific membrane antigen positron emission tomography (PSMA-PET) has been established as a front-line imaging modality. The increasing number of PSMA-PET scans performed in the primary staging setting might be associated with decreases in biochemical recurrence (BCR)-free survival (BCR-FS). Objective To assess
-
Re: Peter Ka-Fung Chiu, Veeru Kasivisvanathan, Giorgio Gandaglia, European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Moving the Needle: Antibiotic Prophylaxis Is No Longer Required in the Era of Transperineal Prostate Biopsy. Eur Urol. 2023;84:154–55 Eur. Urol. (IF 23.4) Pub Date : 2023-07-21 Peter Mærhe Lauritzen, Maciej Jacewitz, Eduard Baco, Erik Rud
Abstract not available
-
Re: Sexual Behavior Shapes Male Genitourinary Microbiome Composition Eur. Urol. (IF 23.4) Pub Date : 2023-07-20
Abstract not available
-
Re: Gyrithe Lynghøj Pedersen, Marie Schmidt Erikson, Karin Mogensen, Susanne Rosthøj, Gregers Gautier Hermann. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Eur. Urol. (IF 23.4) Pub Date : 2023-07-20
Abstract not available
-
Re: Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting Eur. Urol. (IF 23.4) Pub Date : 2023-07-20
Abstract not available
-
Re: Real-time Changes in Brain Activity During Tibial Nerve Stimulation for Overactive Bladder: Evidence from Functional Near-infrared Spectroscopy Hype Scanning Eur. Urol. (IF 23.4) Pub Date : 2023-07-14
Abstract not available
更新日期：2023-09-23
Copyright © 2014-2023 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号